Explained: The new drug for Alzheimers disease Explained News

Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions. The approval will bring massive financial gains for Biogen, which saw its shares gain 38 per cent after the…

Square, Inc Invests $50 Million in Bitcoin

Square started partnering with other companies to expand Square Capital to small businesses that don’t use Square’s point-of-sale platform in an effort to continue growing originations. It also applied for a bank license in order to increase its take on those loans, but it later withdrew its application, tabling those plans. The growth of its…

parytet Słownik języka polskiego PWN

Niestety po jakiś czasie niektóre państwa zaczęły borykać się z deficytami budżetowymi, które były spowodowane przez małą zmienność kursów walutowych. W pewnym momencie doszło do absurdalnej sytuacji w której to złoto było notowane w dwóch różnych cenach, sytuacja ta zapoczątkowała rozpad porozumienia. Należy pamiętać, że parytet siły nabywczej waluty jest koncepcją teoretyczną, która pozwala na…

Cost‐effectiveness of aducanumab to prevent Alzheimer’s disease progression at current list price PMC

Findings  In this decision analytic modeling study based on clinical trial data, neither aducanumab nor donanemab was cost-effective at their expected prices of more than $25 000/y. Aducanumab became cost-effective when priced below $3000/y, whereas owing to its possibly greater efficacy (based on phase 2 trial data) and limited-duration dosing, donanemab was cost-effective when priced around…